Overview
CJC-1295 without DAC is a synthetic peptide developed as a derivative of natural growth hormone-releasing hormone (GHRH). This peptide consists of 29 amino acids and is also known as Mod GRF (1-29). It was designed to retain the properties of natural GHRH while being more stable in research settings.
In the 1980s, scientists discovered that the first 29 amino acids of the original GHRH hormone were sufficient to maintain the same biological activity as the full molecule. However, the disadvantage of these early variants was their short lifespan in the body. Therefore, CJC-1295 was developed as a modified version that would be more resistant to enzyme degradation.
The DAC-free version does not contain the Drug Affinity Complex (DAC), an additive that normally extends the duration of action. Therefore, CJC-1295 without DAC is considered a shorter-acting peptide, making it attractive for specific research protocols.
How does CJC-1295 without DAC work, according to research?
CJC-1295 without DAC is designed to bind to the GHRH receptor in the pituitary gland, the gland responsible for growth hormone secretion. Researchers hypothesize that this binding can trigger a series of cellular signals that ultimately lead to the production and release of growth hormone (GH).
When this receptor is activated, internal signaling processes involving messenger substances such as cAMP can be initiated. These processes may play a role in:
- Activation of proteins within the cell
- Regulation of gene expression
- Stimulation of growth hormone synthesis
As a result, growth hormone-containing vesicles can fuse with the cell membrane, triggering the release of growth hormone.
Structural modifications to the peptide
CJC-1295 without DAC differs from the native GRF fragment by four specific amino acid changes. These modifications were developed to improve stability and biological activity:
- Position 2: Replacement of L-alanine with D-alanine to slow degradation
- Position 8: Replacement of asparagine with glutamine to reduce chemical instability
- Position 15: Replacement of glycine with alanine to support bioactivity
- Position 27: Replacement of methionine with leucine to reduce oxidation
These modifications likely help the peptide remain intact longer during research.
Research on growth hormone and IGF-1
Several studies on modified GRF variants suggest that CJC-1295, without DAC, can influence the GH–IGF-1 axis, a key biological system involved in growth and repair processes.
Experimental studies reported the following observations, among others:
- An increase in average growth hormone secretion by approximately 70–107% over 12 hours
- An increase in IGF-1 levels by approximately 28%
- Indications of increased skin cell activity
- Increases in muscle tissue hypertrophy and muscle mass
These results suggest a potential role for the peptide in processes such as tissue growth and cell renewal, although further studies are necessary to fully understand the exact mechanisms.
Potential research areas
Besides growth hormone research, CJC-1295 without DAC is also being investigated in other experimental areas:
Gut function
Studies with GHRH analog peptides suggest a potential interaction with receptors in the gastrointestinal tract, which could influence gut motility. This connection is being further investigated.
Cardiac research
Preliminary animal studies indicate that GHRH analogs may be involved in cardiac tissue repair processes and support pump function after cardiac injury. However, these findings are still in the early stages of research.
Combination research with other peptides
Because CJC-1295 has a relatively short duration of action without DAC, it is often studied in research settings in combination with other growth hormone secretagogues (GHS). These substances mimic the hormone ghrelin and activate other receptors that are also involved in growth hormone release.
A frequently studied combination is with Ipamorelin. Both peptides stimulate the pituitary gland via different mechanisms, leading researchers to hypothesize a possible synergistic effect on growth hormone secretion.
In short
CJC-1295 without DAC is a modified GHRH analog developed to be more stable than natural growth hormone fragments. Research suggests that the peptide may be involved in:
- Stimulation of growth hormone release
- Modulation of the GH–IGF-1 axis
- Cell growth and tissue research
- Potential synergistic effects with other peptides
While the research results are promising, the precise mechanisms of action are still being investigated in scientific studies.
Buy CJC-1295 NO DAC for research
For researchers seeking high-quality CJC-1295 NO DAC for laboratory studies, Biomedics Lab offers only carefully lab-tested research peptides. Our products meet strict quality standards and are intended solely for research use.
